Skip to main content

がん免疫療法市場は世界的なビジネス予測2030年に急成長しています


The global cancer immunotherapy market was valued at $45,471 million in 2015, and is projected to reach $117,114 million by 2022, growing at a CAGR of 14.5% from 2016 to 2022. The monoclonal antibodies segment held two-third share of the total market in 2015.

Cancer immunotherapy, also known as biologic therapy, helps in cancer treatment by boosting the immunity of the body to fight against cancer. In this type of therapy antibodies and live viruses are introduced in the body that slows the growth of cancer cells. In addition, it also helps the immune system destroy the cancer cells. The major factors that drive the growth of this market include increase in incidence of cancers, growth in geriatric population, and rise in cancer R&D. However, shortage of skilled labor and lack of awareness about cancer immunotherapy is projected to restrain the market growth during the forecast period.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2244

The cancer immunotherapy market in this report is studied on the basis of technology, application, end-user, and region. Based on technology, the market is divided into monoclonal antibodies, cytokines & immunomodulators, and other technologies. Monoclonal antibodies held the largest share in 2015 owing to high usage of monoclonal antibodies for cancer immunotherapy as they exhibit different immunomodulatory properties and hence they can directly activate or inhibit the molecules of immune system. In addition, monoclonal antibodies also induce the antitumor immune response.

By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2015 and is expected to lead the market during the analysis period owing to high incidence of lung cancer. Hospitals in end users held the largest market share of cancer immunotherapy market in 2015, and is projected to show the highest growth rate during the analysis period due to the extensive use of cancer immunotherapy in the hospitals.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2244

Geographically, the global cancer immunotherapy market is analyzed by four regions, namely, North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2015. This is attributed to the ample amount of expenditure in healthcare, well-established healthcare system, and high incidence of cancer. However, Asia-Pacific region is projected to be grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.

The Major Key Players Are:

Amgen Inc., Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., and Astrazeneca plc.

Key Findings of the Cancer Immunotherapy Market:

  • The monoclonal antibody accounted for the largest market share for technology segment in 2015 and is also estimated to grow at the highest CAGR of 15.0%.
  • By application, lung cancer held the highest market share and is anticipated to lead the market during the analysis period.
  • The U.S. was the major shareholder in the North American cancer immunotherapy market, accounting for six-seventh share in 2015.
  • China is expected to show the highest growth rate during the analysis period for the Asia-Pacific cancer immunotherapy market.

Access Full Report @ https://www.alliedmarketresearch.com/cancer-immunotherapy-market

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: 
https://www.alliedmarketresearch.com

Comments

Popular posts from this blog

電子健康記録(EHR)市場 ガーナーへ $33.29 Bn, グローバルに, で 5.0% CAGR

T he global   Electronic Health Records (EHR) Market   generated $24.90 billion in 2017, and is expected to generate $33.29 billion by 2023, registering a CAGR of 5.0% from 2017 to 2023. The report offers a detailed analysis of drivers & opportunities, market size & estimations, top winning strategies, key segments, and competitive scenario. Increase in acceptance of cloud-based EHR software worldwide, surge in incidence of chronic diseases, and rise in ageing population drive the growth of the global EHR market. However, expensive EHR software and rise in concerns regarding data security & safety hinder the growth of the industry. On the other hand, untapped potential in emerging countries create lucrative opportunities in the future. Download Sample Report at:   https://www.alliedmarketresearch.com/request-sample/4542 Based on product, the cloud-based software segment is expected to register the highest CAGR of 5.3% from 2017 to 2023, owing to the less upfront costs and l

ライフサイエンス試薬市場、トレンド、分析、機会、シェア、2019-2027年までの予測

  " Life Science Reagents Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report." Life Science Reagents Market Research has offered exhaustive analysis of Manufacturers, Suppliers, Regions, Type and Application, Forecast to 2027. And also provides essential study on the current status of the market, cover market size with respect to valuation as sales volume and providing a precise prediction of the market scenario over the forecast period from 2020 to 2027. Download Free Sample PDF@   https://www.alliedmarketresearch.com/request-sample/12658 The report provides revenue forecast with sales, sales growth rate, and revenue growth rate forecasts of the global    Life S

副鼻腔拡張デバイス市場 Expected to Reach $5,778 Million by 2023 - Allied Market Research

  Sinus Dilation Devices Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023 ," the global sinus dilation devices market was valued at   $3,326 million   in 2016, and is projected to reach   $5,778 million   at a CAGR of 8.1% from 2017 to 2023. Sinusitis is a medical condition wherein inflammation of sinus lining leads to a plugged nose, headache, poor sense of smell, sore throat, and cough. It is caused due to either ostial blockage, bacterial infections, viral infections, or a combination of these conditions. This leads to use of sinus dilation devices during surgical procedures to dilate the sinus openings of a patient's nose. Request for Sample Report at:   https://www.alliedmarketresearch.com/request-sample/2128 The major factors that drive the global sinus dilation devices market are increase in incidence of sinusitis, which may lead to higher sinus surgeries, high adoption of minimally invasive surgical procedures, and technologi